# US 2021/0263034 A1 · Data processing system for identifying a therapeutic agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0263034 A1
- Document ID: US20210263034A1
- Status: Published application
- Kind: A1
- Application number: 17/144,108
- Filed: 2021-01-07
- Published: 2021-08-26
- Earliest claimed: 2015-03-03
- Assignees: Caris MPI, Inc.
- Applicants: Caris MPI, Inc.
- Inventors: David Spetzler; Brian Abbott; Philip Ellis; Sandeep Reddy
- Web page: https://patentgrep.com/patent/US20210263034A1

## CPC

- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- A61K 31/335: having oxygen as the only ring hetero atom, e.g. fungichromin
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Y 201/01045: Thymidylate synthase (2.1.1.45)
- C12Y 201/01063: Methylated-DNA-[protein]-cysteine S-methyltransferase (2.1.1.63), i.e. O6-methylguanine-DNA methyltransferase
- C12Y 301/03048: Protein-tyrosine-phosphatase (3.1.3.48)
- C12Y 599/01002: DNA topoisomerase (5.99.1.2)
- G01N 33/5751: of the skin, e.g. melanoma
- G01N 33/57515: of the breast
- G01N 33/5752: of the lungs
- G01N 33/57525: of the liver or pancreas
- G01N 33/5753: of the stomach or small intestine
- G01N 33/57535: of the large intestine, e.g. colon, rectum or anus
- G01N 33/57545: of the ovaries
- G01N 33/57555: of the prostate
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- G01N 33/57575: {involving oncogenic proteins}
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B 20/10: Ploidy or copy number detection
- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- G16B 20/40: Population genetics; Linkage disequilibrium
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- G01N 2333/435: from animals; from humans
- G01N 2333/70521: CD28, CD152
- G01N 2333/70532: B7 molecules, e.g. CD80, CD86
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G01N 2333/723: Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
- G01N 2333/82: Translation products from oncogenes
- G01N 2333/9029: acting on -CH2- groups (1.17)
- G01N 2333/91017: with definite EC number (2.1.1.-)
- G01N 2333/916: acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N 2333/99: Isomerases (5.)
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for the disease, such as treatments that provide likely benefit or likely lack of benefit for the disease.

## Claims

### Claim 1

A data processing system for identifying a therapeutic agent for an individual with a cancer, comprising:
one or more computers;
one or more memory devices, wherein the one or more memory devices store:
(i) a database having one or more fields structuring data that includes:
a. a reference value for each of a plurality of genes or gene products, and
b. a listing of available therapeutic agents with efficacy known to be related to at least one of a plurality of gene or gene products,
and
(i) instructions that, when executed by the one or more computers, cause the one or more computers to perform operations, the operations comprising:
generating, by the one or more computers, an assay a plurality of first genes or gene products in a biological sample from the individual to determine molecular profile test values for the plurality of genes or gene products;
determining, by the one or more computers and based on an analysis of the molecular profile test values and a corresponding reference value for each of the plurality of first genes or gene products accessed from the database, one or more therapeutic agents from the listing of available therapeutic agents stored in the database;
generating, by the one or more computers, data that, when processed by the one or more computers, causes the one or more computers to display data that identifies the one or more therapeutic agents.

### Claim 2 (depends on 1)

The data processing system of claim 1, wherein determining, by the one or more computers and based on an analysis of the molecular profile test values and a corresponding reference value for each of the plurality of first genes or gene products accessed from the database, one or more therapeutic agents from the listing of available therapeutic agents stored in the database comprises:
determining, by the one or more computers a likely benefit or lack benefit of the at least one therapeutic agent based on a comparison of the molecular profile test values and a corresponding reference value for each of the plurality of first genes or gene products accessed from the database.

### Claim 3

A method comprising:
generating, by the one or more computers, an assay a plurality of first genes or gene products in a biological sample from the individual to determine molecular profile test values for the plurality of genes or gene products;
determining, by the one or more computers and based on an analysis of the molecular profile test values and a corresponding reference value for each of the plurality of first genes or gene products accessed from a database, one or more therapeutic agents from the listing of available therapeutic agents stored in the database; and
generating, by the one or more computers, data that, when processed by the one or more computers, causes the one or more computers to display data that identifies the one or more therapeutic agents.

### Claim 4 (depends on 3)

The method of claim 3, wherein determining, by the one or more computers and based on an analysis of the molecular profile test values and a corresponding reference value for each of the plurality of first genes or gene products accessed from a database, one or more therapeutic agents from the listing of available therapeutic agents stored in the database includes:
determining, by the one or more computers a likely benefit or lack benefit of the at least one therapeutic agent based on a comparison of the molecular profile test values and a corresponding reference value for each of the plurality of first genes or gene products accessed from the database.

### Claim 5

A computer readable medium storing instructions that, when executed by one or more computers, causes the one or more computers to perform operations that comprise:
generating, by the one or more computers, an assay a plurality of first genes or gene products in a biological sample from the individual to determine molecular profile test values for the plurality of genes or gene products;
determining, by the one or more computers and based on an analysis of the molecular profile test values and a corresponding reference value for each of the plurality of first genes or gene products accessed from a database, one or more therapeutic agents from the listing of available therapeutic agents stored in the database; and
generating, by the one or more computers, data that, when processed by the one or more computers, causes the one or more computers to display data that identifies the one or more therapeutic agents.

### Claim 6 (depends on 5)

The method of claim 5, wherein determining, by the one or more computers and based on an analysis of the molecular profile test values and a corresponding reference value for each of the plurality of first genes or gene products accessed from a database, one or more therapeutic agents from the listing of available therapeutic agents stored in the database includes:
determining, by the one or more computers a likely benefit or lack benefit of the at least one therapeutic agent based on a comparison of the molecular profile test values and a corresponding reference value for each of the plurality of first genes or gene products accessed from the database.
